Pharma Segment Growth
Pharma segment saw a core sales increase of 2%, driven by strong demand for dosing and dispensing technologies, especially in central nervous system applications, asthma, and COPD therapeutics. Injectables core sales increased 18%.
Strategic Acquisition in Brazil
Aptar signed an agreement to acquire Sommaplast, a Brazil-based provider of oral dosing pharma packaging solutions. This acquisition is expected to reinforce Aptar's footprint in Brazil and capitalize on growth in the oral dosing market.
Shareholder Returns
Aptar plans to continue returning capital to shareholders through share repurchases and increased dividends. 2025 has been a banner year for share repurchases, and the quarterly dividend was increased by nearly 7% to $0.48 per share.
Innovations and Approvals
Aptar's HeroTracker Sense technology received FDA 510(k) clearance. The company also inaugurated its expanded pharma research and development center in France, enhancing capabilities across its proprietary drug delivery business.